Albireo to Present at Upcoming Investor Conferences
02 September 2021 - 2:30PM
Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease
company developing novel bile acid modulators, today announced that
Ron Cooper, President and Chief Executive Officer, Simon Harford,
Chief Financial Officer and other members of the Company’s
management team will be presenting at the following investor
conferences:
- 2021 Virtual Wells Fargo Healthcare
ConferenceThursday, September 9 at 9:20 a.m. ET
- H.C. Wainwright 23rd Annual Global Investment
ConferenceMonday, September 13 at 7:00 a.m. ET
- Baird 2021 Global Healthcare
ConferenceTuesday, September 14 at 9:40 a.m. ET
The webcasts of the presentations will be accessible from the
Media & Investors page of Albireo’s website,
ir.albireopharma.com. To ensure a timely connection to the
webcasts, it is recommended that users register at least 15 minutes
prior to the scheduled start times. An archived version of the
webcasts will be available for replay in the Events &
Presentations section of the Media & Investors page of
Albireo’s website for 30 days following the event.
About AlbireoAlbireo Pharma is a rare disease
company focused on the development of novel bile acid modulators to
treat rare pediatric and adult liver diseases. Albireo’s product,
Bylvay, was approved by the U.S. FDA as the first drug for the
treatment of pruritus in all types of progressive familial
intrahepatic cholestasis (PFIC), and is also being developed to
treat other rare pediatric cholestatic liver diseases with Phase 3
trials in Alagille syndrome and biliary atresia, as well as an
Open-label Extension (OLE) study for PFIC. In Europe, Bylvay has
been approved for the treatment of PFIC and has been submitted for
pricing and reimbursement approval. The Company has also initiated
a Phase 1 clinical trial for A3907 to advance development in adult
cholestatic liver disease, with IND-enabling studies moving ahead
with A2342 for viral and cholestatic liver disease. Albireo was
spun out from AstraZeneca in 2008 and is headquartered in Boston,
Massachusetts, with its key operating subsidiary in Gothenburg,
Sweden. The Boston Business Journal named Albireo one of the 2020
Best Places to Work in Massachusetts for the second consecutive
year. For more information on Albireo, please visit
www.albireopharma.com.
Media Contact: Colleen
Alabiso, 857-356-3905, colleen.alabiso@albireopharma.comLauren
Sneider, 857-300-1737, lauren.sneider@albireopharma.com
Investor Contact: Hans Vitzthum, LifeSci
Advisors, LLC., 617-430-7578
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Apr 2023 bis Apr 2024